Empagliflozin (JARDIANCE®) is proven to go beyond lowering A1C to reduce the risk of CV death for adults who have type 2 diabetes and heart disease

Empagliflozin (JARDIANCE^®) is proven to go beyond lowering A1C to reduce the risk of CV death for adults who have type 2 diabetes and heart disease

Early initiation to improve quality of life

Document ID: PC-PH-105101

04/01/2024

Author: Boehringer Ingelheim

Related content